new glp-1 drug retatrutide for Weight Loss: TRIUMPH-1 Results, Cost, Insurance Retatrutide - LeadWest Medical
Description
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
This twice daily injection established the drug class in clinical practice as adjunct therapy for adults not adequately controlled on oral agents
Likewise, daily liraglutide treatment downregulated lung C-C motif chemokine ligand 2 (Ccl2) and IL-6 in mice during influenza infection
The increasing incidence of lifestyle-related diseases in the Asia Pacific is increasing the demand for GLP-1 drugs
Cells 11 , 14655 (2022)
